Primary hepatic diffuse large B-cell lymphoma presenting unusual imaging features

2020 ◽  
Vol 13 (6) ◽  
pp. 1265-1272
Author(s):  
Kumi Ozaki ◽  
Hiroshi Ikeno ◽  
Kenji Koneri ◽  
Shohei Higuchi ◽  
Nahoko Hosono ◽  
...  
Open Medicine ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. 49-51 ◽  
Author(s):  
Tao Wang ◽  
Mingming Zhang ◽  
Jianrong Sun ◽  
Dong Hao ◽  
Zhijiang Qi ◽  
...  

AbstractPrimary pulmonary diffuse large B-cell lymphoma (PPDLBCL) is extremely rare. Its clinical symptoms and signs are nonspe cific, and imaging features also have not yet been well-defined. Further description is important for the diagnosis and treatment of PPDLBCL. Herein, we reported a case of a patient who suffered from bilateral chest pain and dyspnea. Computed tomography (CT) of chest demonstrated bilateral lung mass, consolidations and reverse halo sign, while consolidations and reverse halo sign are uncommon according to previous reports. Tissue samples were taken by CT guided needle biopsy. The histological samples showed PPDLBCL. This case was special in view of positive expression of CD5. After the case was treated by cyclophosphamide pirarubicin vindesine dexamethasone (CHOP) chemotherapy for six courses, her clinical symptoms were partially alleviated, while CT showed progression disease. This case report highlights different imaging features and characteristics of molecular biology, and reviews study progress of PPDLBCL.


2021 ◽  
Vol Volume 13 ◽  
pp. 7289-7297
Author(s):  
Chae Hong Lim ◽  
Sang Eun Yoon ◽  
Won Seog Kim ◽  
Kyung-Han Lee ◽  
Seok Jin Kim

2015 ◽  
Vol 44 (3) ◽  
pp. 290-293 ◽  
Author(s):  
Ekta Dhamija ◽  
Kumble S. Madhusudhan ◽  
Shalimar ◽  
Prasenjit Das ◽  
Deep N. Srivastava ◽  
...  

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.


Sign in / Sign up

Export Citation Format

Share Document